Erasca (ERAS) investor relations material

Executive summary

• Focused on developing therapies for RAS/MAPK pathway-driven cancers, with two clinical-stage programs and a discovery-stage antibody program.

• Advanced ERAS-0015 clinical development ahead of schedule, showing robust efficacy and favorable safety in RAS-mutant solid tumors, including KRAS G12X NSCLC and PDAC.

• Entered collaborations with Merck and Tango Therapeutics for combination trials with KEYTRUDA and vopimetostat.

• Expanded global rights for ERAS-0015 and terminated naporafenib program to prioritize RAS-targeting franchise.

• Strengthened balance sheet with significant equity offerings.

Financial highlights

• Net loss of $183.4 million for Q1 2026, compared to $31.0 million for Q1 2025, driven by a $150.0 million in-process R&D expense related to a license agreement.

• Operating expenses rose to $187.9 million from $35.6 million year-over-year.

• Research and development expenses were $27.3 million, up from $26.0 million year-over-year; $150 million in-process R&D expense for global license expansion.

• General and administrative expenses increased to $10.6 million from $9.7 million year-over-year.

• Cash, cash equivalents, and marketable securities totaled $408.5 million as of March 31, 2026, up from $341.8 million at year-end 2025.

Outlook and guidance

• Cash, cash equivalents, and marketable securities expected to fund operations into the second half of 2028.

• No product revenue expected for several years; continued reliance on equity and other financings.

• ERAS-0015 monotherapy expansion and combination data expected in H1 2027; ERAS-4001 Phase 1 preliminary data expected in H2 2026.